CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Rituximab -CHOP plus Velcadedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00169468
NCT00169468Phase 2Completed
CompareCT.gov

Phase II Study of the Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

Lymphoma Study Association·interventional·Posted Sep 15, 2005·Updated Aug 23, 2018

In Brief

A Phase 2 clinical trial evaluating Rituximab -CHOP plus Velcade for B Cell Lymphoma. Completed, enrolled 48 participants across 4 sites.

Detailed Summary

The primary objective of this study is to evaluate the response rate and toxicity of the association R-CHOP with two schedules of administration of Velcade, in B-cell CD 20 + lymphoma patients, aged from 18 to 80 years The goal is to get a response rate at least at what observed with R-CHOP alone and will be evaluates with a sequential test. The other objective is to evaluate the toxicity

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB Cell Lymphoma
CountriesFrance
CollaboratorsAssociation pour le Développement de la Recherche Clinique et Informatique en Onco-Hématologie

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartJan 1, 2005
Primary CompletionJan 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 20.8 years ago

Interventions

Rituximab -CHOP plus Velcadedrug